PALOMA3_2A | R Documentation |
Kaplan-Meier digitized data from PALOMA3, figure 2A (PMID 26947331). A reported sample size of 521 for a primary endpoint of PFS in breast cancer.
PALOMA3_2A
A data frame of 521 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (fulvestrant_palbociclib, fulvestrant_placebo) | |
Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016; 17: 425–39.
summary(PALOMA3_2A)
kmplot(PALOMA3_2A)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.